• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » vfa CEO responds to German pharmaceutical policy changes

vfa CEO responds to German pharmaceutical policy changes

March 3, 2014
CenterWatch Staff

The German Bundestag is implementing a number of pharmaceutical policy changes within the scope of the 14th law amending Book V of the German Social Code, including an extension of the drug price freeze to 2017.

Birgit Fischer, CEO of vfa, commented on behalf of researching pharmaceutical companies, saying, “The law will set an important direction for the German healthcare system. The benefit assessment of the existing market, which is considered by the Joint Federal Committee (GBA) to be barely feasible will, for example, be abolished. Also, in view of the high surpluses of the health insurers, the mandatory discount of the pharmaceutical industry will be decreased. We welcome both of these decisions, which we also believe are correct.”

“However, freezing the prices of medicinal products in Germany with a long-time price moratorium without compensation for inflation will disempower the pharmaceutical companies, leading to a situation which can no longer be deemed a market economy,” she said. “Cost increases for companies cannot be passed on and refinanced. This in turn leads to gradual expropriation, giving rise to serious constitutional concerns. Between 2009 and 2013, the financial burden on the industry resulting from the price moratorium alone has amounted to about $2.75 billion. If the price freeze to the price level of 2009 continues, the yearly financial burden will increase to $1.4 billion in 2014 and $1.65 billion in 2015. A long-standing price moratorium thus at least requires consideration of the general price development. In our opinion, this should be done by adjusting the price level to the rate of inflation and should be restricted to a clearly limited time frame.”

Fischer concluded, “Clearly, not enough time was dedicated to the legislation process, leaving insufficient time to consider the consequences and for discussion. The politicians have not done themselves a favor with this. It has not been sufficiently discussed how the fixed-price system and reimbursement system will harmonize with one another in the future without jeopardizing the healthcare system. We are risking a trial and error procedure of the healthcare system at the patients’ expense.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing